- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07836478
Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)
Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor
Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.
Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.
The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.
The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.
From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.
Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Gabriella Pravettoni
- Telefonnummer: +39 0257489207
- E-mail: Gabriella.Pravettoni@ieo.it
Studiesteder
-
-
Italy
-
Milan, Italy, Italien, 20141
- European Institute of Oncology, Milan
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment
Beskrivelse
Inclusion Criteria:
- Primary tumors of Brain Tumor (CNS), benign and malignant
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
- Radiological diagnosis, biopsy, or previous surgery
- Concomitant medical therapy is allowed
Exclusion Criteria:
- Previous brain radiotherapy (any form)
- High-grade gliomas
- Patients with concomitant neurological or psychiatric disorders.
- Pregnancy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The presence of cognitive impairment
Tidsramme: From the end of Protontherapy through study completion, an average of 1 year.
|
The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment. |
From the end of Protontherapy through study completion, an average of 1 year.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Perceived cognitive impairment
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Depressive symptoms
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Anxiety
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For EORTC QLQ C30, 30 items will be completed (score 1-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Sleep quality
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Cognitive Reserve
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Global functioning
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Learning and Verbal Memory
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Working memory
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Corsi Span backward/forward 18 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visual memory
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visuospatial abilities
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Executive function
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Attention
Tidsramme: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- UID 5445
- L2-684 (Anden identifikator: Comitato Etico Lombardia 2)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .